- South Africa
- /
- Pharma
- /
- JSE:AIP
Adcock Ingram Holdings Full Year 2024 Earnings: EPS: R5.40 (vs R5.61 in FY 2023)
Adcock Ingram Holdings (JSE:AIP) Full Year 2024 Results
Key Financial Results
- Revenue: R9.64b (up 5.6% from FY 2023).
- Net income: R814.0m (down 9.4% from FY 2023).
- Profit margin: 8.4% (down from 9.8% in FY 2023). The decrease in margin was driven by higher expenses.
- EPS: R5.40 (down from R5.61 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Adcock Ingram Holdings Earnings Insights
The primary driver behind last 12 months revenue was the Prescription segment contributing a total revenue of R3.43b (36% of total revenue). Notably, cost of sales worth R6.46b amounted to 67% of total revenue thereby underscoring the impact on earnings. The largest operating expense was Sales & Marketing costs, amounting to R1.34b (57% of total expenses). Explore how AIP's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 5.7% p.a. on average during the next 2 years, compared to a 9.3% growth forecast for the Pharmaceuticals industry in Africa.
Performance of the market in South Africa.
The company's shares are up 17% from a week ago.
Risk Analysis
We don't want to rain on the parade too much, but we did also find 1 warning sign for Adcock Ingram Holdings that you need to be mindful of.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About JSE:AIP
Adcock Ingram Holdings
Engages in the manufacture, marketing, and distribution of healthcare products to private and public sectors in Southern Africa and India.
Flawless balance sheet second-rate dividend payer.
